<DOC>
	<DOC>NCT00189813</DOC>
	<brief_summary>This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.</brief_summary>
	<brief_title>A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patient meets Rome II criteria for IBS and the subgroup of diarrhea predominant IBS Patient with severe cardiovascular disease, respiratory diseases, renal diseases, hepatic diseases, digestive tract diseases (excluding IBS), blood diseases, or neurological or psychiatric diseases Patient reported having any Type 1 or Type 2 stool on the Bristol Stool Form Scale during the runin period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Nasea®</keyword>
	<keyword>Irribow®</keyword>
	<keyword>ramosetron</keyword>
</DOC>